Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen

A case report

Adrienn Tünnemann-Tarr, MD, Hubert Scharnagl, PhD, Julius L. Katzmann, MD, Paulina Stürzebecher, MD, Ulrich Laufs, MD

Abstract

Rationale: Familial chylomicronemia syndrome is a congenital, severe form of hypertriglyceridemia associated with increased risk of acute pancreatitis. Treatment options are limited.

Patient concerns: A 52-year-old woman was referred with recurrent pancreatitis and severe hypertriglyceridemia to our lipid clinic.

Diagnosis: Laboratory examination showed elevated serum triglyceride concentrations of 8090 mg/dL (90 mmol/L). Lipid electrophoresis showed a type V phenotype with positive chylomicrons. Genetic investigation revealed a novel heterozygous large deletion of the lipoprotein lipase gene on chromosome 8. A familial chylomicronemia syndrome was diagnosed. Other causes of hypertriglyceridemia were excluded.

Interventions: Fibrates and diet did not lower triglyceride levels. Therefore, treatment with the apolipoprotein CIII (apoCIII) inhibitor volanesorsen was initiated.

Outcomes: After 3 months of treatment, a 90% reduction of triglycerides was observed. ApoCIII concentrations were reduced by 90% in the total and by 61% in the chylomicron-free serum. Treatment was well tolerated with only minor local reaction after the first application. The platelet count was monitored weekly and did not decrease < 150 cells/µL.

Lessons: This case report shows that inhibition of apoCIII potently reduces serum triglycerides in patients with heterozygous monogenetic deletion of the lipoprotein lipase gene. Follow-up will show the effect on recurrent episodes of pancreatitis.

Abbreviations: apoCIII = apolipoprotein CIII, FCS = familial chylomicronemia syndrome, LPL = lipoprotein lipase, mRNA = messenger ribonucleic acid, (V)LDL = (very) low-density lipoprotein.

Keywords: apolipoprotein CIII inhibitor, familial chylomicronemia syndrome, hypertriglyceridemia, pancreatitis, volanesorsen

1. Introduction

Familial chylomicronemia syndrome (FCS) is a congenital, severe form of hypertriglyceridemia, caused by mutations of the lipoprotein lipase (LPL) gene.[1] LPL catalyzes lipolysis in triglyceride-rich lipoproteins such as chylomicrons. LPL deficiency leads to highly elevated triglyceride and chylomicron serum concentrations. FCS is associated with an increased risk of acute pancreatitis, a potentially life-threatening disease. The diagnosis of FCS is often delayed until adulthood.[2] The estimated prevalence of the FCS is 1 to 10 per million.[3] We report a case of FCS that is of interest because of a novel mutation, a heterozygote large deletion within the chromosome 8, and the effects of treatment with the apolipoprotein CIII (apoCIII) inhibitor volanesorsen on serum lipoproteins.

2. Case report

In 2019, a 52-year-old woman presented to our lipid clinic. During the previous year, she was hospitalized twice with severe acute pancreatitis. The patients’ medical history included a history of breast cancer on the left side, treated with ablation and radio- and chemotherapy. The patient had a well-controlled diabetes mellitus type 2 with an HbA1c of 6.3%. The son of the patient has elevated triglyceride levels.
Laboratory examination showed a markedly elevated triglyceride level of 8090 mg/dL (90 mmol/L). The refrigeration test was positive (Fig. 1). The lipoprotein electrophoresis showed a type V hyperlipoproteinemia phenotype with positive chylomicrons. Other secondary factors contributing to hypertriglyceridemia (such as alcohol consumption, insufficient diet, renal insufficiency, metabolic syndrome, medical induced hypertriglyceridemia, thyroid disease) were excluded.

The patient had no signs of atherosclerotic disease, the intima-media thickness of the common carotid artery was normal with 0.6 mm on both sides.

The FCS score was 10 (positive). Genetic investigation revealed a previously not described heterozygous deletion of the chromosome 8 (Chr;8:18,930,023–20,002,715) (Fig. 2). This large deletion is 1070 kb long and involves 5 protein-coding genes including the whole LPL protein-coding gene explaining the remarkable chylomicronemia.

The patient followed a low fat and low carbohydrate diet. In spite of the usage of bezafibrate for several years, the triglyceride levels did not show any changes and the second episode of severe pancreatitis happened during the fibrate treatment.

To prevent recurrent pancreatitis, treatment with volanesorsen, an antisense oligonucleotide inhibitor of apoCIII, was initiated with a weekly dose of 285 mg.s.c. for the first 3 months.

Lipoprotein separation and analysis was performed from frozen serum samples (stored at −80°C). Lipids and apolipoproteins were measured in fasting total serum and after ultracentrifugation in chylomicron-free serum. Lipids and apolipoproteins in chylomicrons were calculated as difference between serum and chylomicron-free serum. ApoCIII levels showed a 90% decrease in the total serum (120 mg/dL vs 12 mg/dL) and 61% in chylomicron free serum (44 mg/dL vs 17 mg/dL). In the chylomicron fraction, a 96% reduction of the triglyceride level was observed and apoCIII was not measurable (Table 1). Within 3 months, a 90% reduction of triglyceride concentration was observed, with a lowest value of 721 mg/dL (Fig. 3A). In parallel to the decrease of chylomicrons, the concentrations of cholesterol and apolipoprotein B in very low-density lipoproteins (VLDL) and low-density lipoprotein (LDL) increased (Table 1), indicating that lipolysis and the production of cholesterol-rich particles were partially recovered. The treatment was well tolerated. Local reaction occurred only after the first application of the subcutaneous injection. Weekly monitoring showed a mild decrease of the platelet count that was transient (Fig. 3B).

### 3. Discussion

FCS is characterized by fasting blood triglyceride concentrations > 885 mg/dL (> 10 mmol/L) due to chylomicronemia. Chylomicrons are large lipoproteins formed in the intestine during the absorption of dietary fats. In conditions of reduced activity of their primary degrading enzyme, the LPL, chylomicron degradation is impaired causing elevated and persisting serum triglyceride levels.

Symptoms of FCS include severe abdominal pain with or without pancreatitis, leading to metabolic complications and frequent hospitalizations. The typical and most serious complication of chylomicronemia is acute pancreatitis. In the majority of FCS patients, the episodes occur recurrently. Some of the patients develop chronic pancreatitis that can lead to pancreaticophrine diabetes mellitus (type 3). One episode of acute pancreatitis is able to cause permanent damage to the pancreas which is associated with a mortality rate of 6%.

Two mechanisms contribute to the development of pancreatitis. The accumulation of chylomicrons reduces the blood flow to the pancreas, which leads to ischemia. In addition, the triglycerides are degraded to free fatty acids by the pancreatic lipase. The clogged chylomicrons cause acinar damage and exposure of triglycerides to the pancreatic lipase. Due to the release of free fatty acids, acinar damage occurs. The conversion of trypsinogen and trypsin releases inflammatory cytokines. Cytotoxic injury occurs, resulting in an increase in inflammatory mediators and free radicals. The risk of pancreatitis increases with the higher serum triglycerides. Patients with FCS have a 360-fold increased risk of acute pancreatitis.

Additional symptoms of patients with FCS include eruptive xanthomas, arthralgias, lipemia retinalis or hepatosplenomegaly. In addition, there are neurological symptoms such as mild dementia, confusion, memory loss and fatigue. FCS is associated with emotional burden on the patients and their relatives, which can lead to anxiety, feelings of guilt, social isolation, and depression. The social isolation is amplified by the special dietary requirements.

Affected patients usually do not respond to conventional triglyceride-lowering therapies. In the past, treatment of FCS patients was limited to very strict dietary fat restriction and

**Figure 1.** Positive refrigerator test. Shown is a serum specimen stored 24 hours in a refrigerator. In the presence of chylomicrons, these build a creamy layer at the top of the specimen, while the serum becomes clear; in contrast, very-low density lipoprotein remains dissolved in the serum.
avoidance of alcohol and certain medications. Plasmapheresis has been tried in some FCS cases. In the presence of diabetes, intravenous administration of insulin is required. The extremely restrictive diet and the risk of recurrent pancreatitis limits the quality of life. The compliance with the diet regimen over long periods is challenging.

FCS is caused by a rare gene defect that is currently known to affect \textit{LPL}, \textit{APOC2}, \textit{GPHBP1}, \textit{APOA5}, and \textit{LMF1}. Mutations in the \textit{LPL} gene are responsible for the development of 80\% of cases. \textit{LPL} is a key enzyme in the catalysis of triglycerides. Reduced \textit{LPL} function causes chylomicronemia. Until now, 5 deletions of the \textit{LPL} gene have been described in the literature. The new deletion reported in this patient for the first time is hundred times larger than the previously described alterations which likely explains the severe clinical manifestation in our patient.

One of the proteins affecting \textit{LPL} activity is \textit{apoCIII}. \textit{apoCIII} inhibits \textit{LPL} activity, reduces the hepatic uptake of triglyceride-rich lipoproteins and increases hepatic secretion of triglycerides. Loss-of-function (LOF) mutations of the gene coding for \textit{apoCIII} and pharmacologic inhibition of \textit{apoCIII} lead to reduced plasma triglyceride levels. The novel drug volanesorsen selectively binds within the 3\' untranslated region of \textit{apoCIII} messenger ribonucleic acid (mRNA). This binding

### Table 1

| Lipids and apolipoproteins in fasting serum and after ultracentrifugation (chylomicron-free serum and in the chylomicron fraction) during the treatment with volanesorsen. |
|-----------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Start of the treatment with volanesorsen | Week 1 | Week 2 | Week 6 | Week 9 |
| Serum with chylomicrons | | | | |
| Cholesterol | 1292 | 1285 | 1315 | 539 | 293 |
| Triglycerides | 6603 | 9899 | 8421 | 2052 | 841 |
| ApoCIII | 120 | 133 | 106 | 25 | 12 |
| Serum after separation of chylomicrons | | | | |
| Cholesterol | 65 | 88 | 125 | 86 | 195 |
| Triglycerides | 276 | 482 | 640 | 197 | 448 |
| ApoCIII | 44 | 32 | 40 | 26 | 17 |
| Chylomicrons | | | | |
| Cholesterol | 1227 | 1197 | 1190 | 453 | 98 |
| Triglycerides | 6327 | 9417 | 7781 | 1855 | 393 |
| ApoCIII | 76 | 101 | 66 | ND | ND |
| VLDL | | | | |
| VLDL-cholesterol | 30 | 58 | 95 | 23 | 100 |
| VLDL-apoB | 7 | 17 | 21 | 9 | 37 |
| LDL | | | | |
| LDL-cholesterol | 25 | 18 | 18 | 48 | 71 |
| LDL-apoB | 36 | 44 | 45 | 62 | 73 |

All values are given in mg/dL.
(V)LDL = (very) low-density lipoprotein, Apo = apolipoprotein, ND = not determined.
allows mRNA degradation prevents the translation of the apoCIII mRNA and lowers triglycerides.\[19\]

In our patient, volanesorsen rapidly reduced apoCIII serum concentrations and serum triglyceride concentration by 90%. In parallel to the observed reduction of chylomicrons, the concentrations of cholesterol and apolipoprotein B in VLDL and LDL increased showing partial restoration of lipolysis and of cholesterol-rich particles. The treatment was very well tolerated. The only adverse effect was a mild and transient decrease of the platelet count.

In summary, patients with FCS and recurrent pancreatitis have a very high morbidity with limited treatment options.\[20\] This case identifies a novel mutation causing severe FCS and is an example of a novel treatment modality using an RNA-inhibiting drug targeting apoCIII. Prospective studies with clinical endpoints are wanted.

**Author contributions**

AT and UL wrote the article, AT, JLK, PS, and UL diagnosed and treated the patient, HS performed the laboratory analyses. All authors approved the final article.

**Conceptualization:** Adrienn Tünnemann-Tarr, Julius L. Katzmann, Ulrich Laufs.

**Data curation:** Adrienn Tünnemann-Tarr, Julius L. Katzmann.

**Investigation:** Adrienn Tünnemann-Tarr, Hubert Scharnagl, Julius L. Katzmann, Paulina Stürzebecher, Ulrich Laufs.

**Methodology:** Adrienn Tünnemann-Tarr, Hubert Scharnagl, Ulrich Laufs.

**Project administration:** Ulrich Laufs.

**Supervision:** Ulrich Laufs.

**Validation:** Ulrich Laufs.

**Visualization:** Adrienn Tünnemann-Tarr, Julius L. Katzmann.

**Writing – original draft:** Adrienn Tünnemann-Tarr, Ulrich Laufs.

**Writing – review & editing:** Adrienn Tünnemann-Tarr, Hubert Scharnagl, Julius L. Katzmann, Paulina Stürzebecher, Ulrich Laufs.

**References**

[1] Williams L, Rhodes KS, Karmally W, Welstead LA, Alexander L, Sutton L. Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span. J Clin Lipidol 2018; 12:908–19.

[2] Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridemia. J Intern Med 2020;287:340–8.

[3] Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J 2020;41:99–109c.

[4] Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”. Atherosclerosis 2018;275:265–72.

[5] Feingold KR. Endotext: Triglyceride Lowering Drugs. South Dartmouth (MA); 2000.

[6] Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 2014;371:2200–6.

[7] Zhang R, Deng L, Jin T, et al. Hypertriglyceridaemia-associated acute pancreatitis: diagnosis and impact on severity. HPB (Oxford) 2019; 21:1240–9.

[8] Guo YY, Li HX, Zhang Y, He WH. Hypertriglyceridemia-induced acute pancreatitis: progress on disease mechanisms and treatment modalities. Discov Med 2019;27:101–9.

[9] Brunzell JDBE, Bierman EL. Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridaemia. Med Clin North Am 1982;66:455–68.

[10] Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. J Clin Lipidol 2018;12:988e2–907e2.

[11] Zheng Z, Ding Y-X, Qu Y-Y, Cao F, Li F, A narrative review of acute pancreatitis and its diagnosis, pathogenetic mechanism, and management. Ann Transl Med 2021;9:69.

[12] Chang C-T, Tsai T-Y, Liao H-Y, et al. Double filtration plasma apheresis shortens hospital admission duration of patients with severe hypertriglyceridemia-associated acute pancreatitis. Pancreas 2016;45:606–12.

[13] Hegele RA, Borén J, Ginsberg HN, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol 2020;8:50–67.

[14] Dron JS, Wang J, McIntyre AD, et al. Partial LPL deletions: rare copy-number variants contributing towards severe hypertriglyceridemia. J Lipid Res 2019;60:1953–8.
[15] Iacocca MA, Dron JS, Hegele RA. Progress in finding pathogenic DNA copy number variations in dyslipidemia. Curr Opin Lipidol 2019;30:63–70.
[16] West G, Rodia C, Li D, Johnson Z, Dong H, Kohan AB. Key differences between apoC-III regulation and expression in intestine and liver. Biochem Biophys Res Commun 2017;491:747–53.
[17] Borén J, Packard CJ, Taskinen M-R. The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne) 2020;11:474.
[18] Taskinen M-R, Packard CJ, Borén J. Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD. Curr Atheroscler Rep 2019;21:27.
[19] Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med 2019;381:531–42.
[20] Garg R, Rustagi T. Management of hypertriglyceridemia induced acute pancreatitis. Biomed Res Int 2018;2018:4721357.